.png){kind=icon}
.png){kind=icon}
Return
Amivantamab plus chemotherapy vs. chemotherapy as first-line treatment in Chinese mainland patients with EGFR exon 20 insertion non-small cell lung cancer: Subgroup analysis of the randomized PAPILLON trial
.png){kind=icon}
OA
AI
T
W
Y
Y
Z
Z
S
W
L
W
H
L
S
G
P
B
M
L
W
A
Z
DOI：10.1097/CM9.0000000000004134.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
First-line amivantamab plus carboplatin-pemetrexed demonstrated efficacy and an acceptable safety profile in the PAPILLON trial (NCT04538664) in patients with advanced non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 20 insertions; we report the efficacy and safety results of the Chinese mainland subgroup population from the PAPILLON study.
Keywords:
Amivantamab
Epidermal growth factor receptor exon 20 insertions
Non-small cell lung cancer
Journal
IF:
7.3
Papers:
1.2W
Citations:
1.5W
Organization
Cited Papers